<DOC>
	<DOCNO>NCT03096457</DOCNO>
	<brief_summary>This protocol compare topical paromomycin standard intralesional ( IL ) antimony ( Sb ) placebo L braziliensis Bolivia .</brief_summary>
	<brief_title>Topical Paromomycin Cutaneous Leishmaniasis Bolivia</brief_title>
	<detailed_description>Patients randomize Paromomycin cream apply topically daily 20 day ( group 1 -- 40 patient ) , pentamidine administer intralesionally 120 ug/mm2 day 1 , 3 , 5 ( group 2—20 patient ) , cream vehicle apply topically daily 20 day ( group 3—20 patient ) . After treatment , patient follow 1 , 3 , 6 month .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Leishmaniasis , Mucocutaneous</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<criteria>Gender : Male female Age : &gt; 12 yr age Presentation : 1to2 ulcerative lesion , &lt; 30 mm large diameter total lesion area &lt; 900 mm2 . Parasitology : Parasitological confirmation lesion make visualization culture Leishmania biopsy aspirate lesion . Previous treatment leishmaniasis Sb , pentamidine , amphotericin B , miltefosine , imidazole , allopurinol last 3 month . Other disease would likely PI 's opinion interact , either positively negatively , treatment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>leishmaniasis</keyword>
	<keyword>L.braziliensis</keyword>
	<keyword>paromomycin cream</keyword>
	<keyword>intralesional pentamidine</keyword>
	<keyword>leishmaniasis local therapy</keyword>
</DOC>